Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Division of Regenerative Medicine, School of Medicine, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK.
Lab Med. 2021 Jul 1;52(4):357-363. doi: 10.1093/labmed/lmaa095.
This study evaluated anti-modified citrullinated vimentin (anti-MCV) performance in determining the clinical picture and outcomes of palindromic rheumatism (PR).
In a retrospective study, patients with PR with at least 1 year of follow-up diagnosed according to clinical criteria were enrolled. Anti-MCV antibodies were measured, and levels >20 IU/mL were considered positive. Disease prognosis was assessed according to patients acquiring remission and preventing PR from developing into rheumatoid arthritis (RA) or other diseases.
Seventy-six patients with PR with a mean follow-up of 30.57 months (median = 21 months; minimum = 12 months; maximum = 48 months) were included in the study. Anti-MCV antibodies were positive in 69.7% of patients. Metacarpophalangeal (MCP) joint involvement and positive anti-cyclic citrullinated peptides were significantly higher in patients who were anti-MCV-positive, whereas ankle joint involvement was significantly lower. No significant correlation was observed between the anti-MCV titer and the severity of attacks. Remission in patients who were anti-MCV-positive and negative was 75.5% and 78.3%, respectively, with no significant difference. Evolution to RA was observed in only 3.8% of patients who were anti-MCV-positive. No patients who were anti-MCV-negative developed RA.
Except for MCP and ankle joint involvement, anti-MCV was not helpful in determining the clinical picture and outcome of PR.
本研究评估了抗修饰波形蛋白（anti-MCV）在确定复发性风湿症（PR）的临床特征和结局方面的性能。
在一项回顾性研究中，纳入了根据临床标准诊断为至少有 1 年随访的 PR 患者。检测了抗-MCV 抗体，将 >20 IU/mL 的水平定义为阳性。根据患者是否获得缓解以及是否预防 PR 发展为类风湿关节炎（RA）或其他疾病来评估疾病预后。
共纳入 76 例 PR 患者，平均随访 30.57 个月（中位数=21 个月；最小=12 个月；最大=48 个月）。69.7%的患者抗-MCV 抗体阳性。抗-MCV 阳性患者的掌指关节（MCP）受累和抗环瓜氨酸肽阳性明显更高，而踝关节受累明显更低。抗-MCV 滴度与发作严重程度之间未观察到显著相关性。抗-MCV 阳性和阴性患者的缓解率分别为 75.5%和 78.3%，差异无统计学意义。仅 3.8%的抗-MCV 阳性患者发展为 RA。无抗-MCV 阴性患者发展为 RA。
除了 MCP 和踝关节受累外，抗-MCV 对 PR 的临床特征和结局无帮助。
